Olstein Capital Management L.P. Sells 14,000 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Olstein Capital Management L.P. lowered its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 28.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,000 shares of the company's stock after selling 14,000 shares during the quarter. Olstein Capital Management L.P. owned 0.07% of Prestige Consumer Healthcare worth $2,524,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Opal Wealth Advisors LLC acquired a new position in shares of Prestige Consumer Healthcare during the second quarter worth about $26,000. Quest Partners LLC grew its position in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company's stock valued at $30,000 after purchasing an additional 424 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Prestige Consumer Healthcare by 80.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company's stock worth $33,000 after purchasing an additional 208 shares in the last quarter. Gladius Capital Management LP bought a new position in shares of Prestige Consumer Healthcare during the second quarter worth approximately $35,000. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company's stock valued at $35,000 after buying an additional 433 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

PBH has been the topic of a number of analyst reports. Jefferies Financial Group reissued a "hold" rating and set a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson increased their target price on Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a "buy" rating in a report on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $94.20.

Prestige Consumer Healthcare Price Performance

PBH traded up $2.43 during trading on Thursday, hitting $80.07. 355,414 shares of the stock traded hands, compared to its average volume of 247,570. The business has a 50 day moving average price of $72.31 and a 200 day moving average price of $69.71. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.23 and a quick ratio of 1.90. Prestige Consumer Healthcare Inc. has a twelve month low of $56.61 and a twelve month high of $81.25. The company has a market cap of $3.97 billion, a price-to-earnings ratio of 18.93, a PEG ratio of 2.08 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 EPS for the quarter, topping analysts' consensus estimates of $0.86 by $0.04. The company had revenue of $267.10 million during the quarter, compared to analysts' expectations of $260.54 million. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. Prestige Consumer Healthcare's revenue was down 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.06 EPS. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.